{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:54:46Z","timestamp":1790873686569,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.seizure.2021.07.011","type":"journal-article","created":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T12:16:28Z","timestamp":1626178588000},"page":"332-338","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Severe cutaneous adverse reactions in Asians: Trends observed in culprit anti-seizure medicines using VigiBase\u00ae"],"prefix":"10.1016","volume":"91","author":[{"given":"Shatrunajay","family":"Shukla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Rastogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayed Aliul Hasan","family":"Abdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puneet","family":"Dhamija","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivekanandan","family":"Kalaiselvan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bikash","family":"Medhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2021.07.011_bib0001","series-title":"Epilepsy: a public health imperative: summary","year":"2019"},{"key":"10.1016\/j.seizure.2021.07.011_bib0002","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1212\/CON.0000000000000709","article-title":"Optimizing management of medically responsive epilepsy","volume":"25","author":"Bauer","year":"2019","journal-title":"Continuum"},{"key":"10.1016\/j.seizure.2021.07.011_bib0003","article-title":"Adverse skin reactions with antiepileptic drugs using Korea adverse event reporting system database, 2008\u20132017","volume":"35","author":"Kim","year":"2019","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.seizure.2021.07.011_bib0004","doi-asserted-by":"crossref","first-page":"64","DOI":"10.12793\/tcp.2019.27.2.64","article-title":"Antiepileptic drug-induced severe cutaneous adverse reactions and HLA alleles: A report of five cases with lymphocyte activation test","volume":"27","author":"Kim","year":"2019","journal-title":"Transl Clin Pharmacol"},{"key":"10.1016\/j.seizure.2021.07.011_bib0005","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.pharep.2014.11.009","article-title":"Antiepileptic drugs and adverse skin reactions: an update","volume":"67","author":"B\u0142aszczyk","year":"2015","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.seizure.2021.07.011_bib0006","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/QCO.0b013e3283298e62","article-title":"Molecular mechanisms of maculopapular exanthema","volume":"22","author":"Fern\u00e1ndez","year":"2009","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.seizure.2021.07.011_bib0007","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/COC.0b013e31825d5835","article-title":"Erythema multiforme, Stevens Johnson syndrome, and toxic epidermal necrolysis syndrome in patients undergoing radiation therapy: a literature review","volume":"37","author":"Vern-Gross","year":"2014","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.seizure.2021.07.011_bib0008","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/2780272","article-title":"Association between HLA-B alleles and carbamazepine-induced maculopapular exanthema and severe cutaneous reactions in Thai patients","volume":"2018","author":"Sukasem","year":"2018","journal-title":"J Immunol Res"},{"key":"10.1016\/j.seizure.2021.07.011_bib0009","first-page":"31","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome","volume":"6","author":"Choudhary","year":"2013","journal-title":"J Clin Aesthet Dermatol"},{"key":"10.1016\/j.seizure.2021.07.011_bib0010","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1097\/CCM.0b013e31821201ed","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome: a review","volume":"39","author":"Gerull","year":"2011","journal-title":"Crit Care Med"},{"key":"10.1016\/j.seizure.2021.07.011_bib0011","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1111\/epi.13925","article-title":"The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptic drugs","volume":"58","author":"Frey","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2021.07.011_bib0012","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/PEC.0000000000001188","article-title":"DRESS syndrome: drug reaction with eosinophilia and systemic symptoms","volume":"33","author":"Corneli","year":"2017","journal-title":"Pediatr Emerg Care"},{"key":"10.1016\/j.seizure.2021.07.011_bib0013","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1097\/MJT.0000000000000037","article-title":"Challenges in diagnosis, management, and treatment of allopurinol-induced DRESS syndrome: case report and literature review","volume":"22","author":"Thankachen","year":"2015","journal-title":"Am J Ther"},{"key":"10.1016\/j.seizure.2021.07.011_bib0014","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1001\/archderm.138.8.1019","article-title":"Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study","volume":"138","author":"Auquier-Dunant","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.seizure.2021.07.011_bib0015","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1212\/WNL.0b013e31823b478c","article-title":"Severe cutaneous adverse reactions to antiepileptic drugs in Asians","volume":"77","author":"Yang","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2021.07.011_bib0016","first-page":"2732","article-title":"Spontaneous reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with antiepileptic drugs","volume":"19","author":"Ordo\u00f1ez","year":"2015","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.seizure.2021.07.011_bib0017","doi-asserted-by":"crossref","first-page":"709","DOI":"10.4168\/aair.2019.11.5.709","article-title":"Severe cutaneous adverse reactions to antiepileptic drugs: a nationwide registry-based study in Korea","volume":"11","author":"Park","year":"2019","journal-title":"Allergy Asthma Immunol Res"},{"key":"10.1016\/j.seizure.2021.07.011_bib0018","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/cpt.1071","article-title":"The medication risk of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis in asians: the major drug causality and comparison with the US FDA label","volume":"105","author":"Wang","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.seizure.2021.07.011_bib0019","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/tan.13530","article-title":"HLA-associated antiepileptic drug-induced cutaneous adverse reactions","volume":"93","author":"Mullan","year":"2019","journal-title":"HLA"},{"key":"10.1016\/j.seizure.2021.07.011_bib0020","series-title":"10th asian & oceanian epilepsy congress","article-title":"HLA-A* 2402 as a common genetic risk factor for aromatic antiepileptic drugs induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese","author":"Min","year":"2014"},{"key":"10.1016\/j.seizure.2021.07.011_bib0021","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3349\/ymj.2016.57.1.118","article-title":"HLA allele frequencies in 5802 Koreans: varied allele types associated with SJS\/TEN according to culprit drugs","volume":"57","author":"Park","year":"2016","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.seizure.2021.07.011_bib0022","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jdermsci.2013.10.003","article-title":"Genotype\u2013phenotype association between HLA and carbamazepine-induced hypersensitivity reactions: strength and clinical correlations","volume":"73","author":"Hsiao","year":"2014","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.seizure.2021.07.011_bib0023","unstructured":"Alert, F. Dangerous or even fatal skin reactions\u2013Carbamazepine (marketed as Carbatrol, Equetro, Tegretol, and generics)\u2013Healthcare Professional Sheet text version. In."},{"key":"10.1016\/j.seizure.2021.07.011_bib0024","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/009286150804200501","article-title":"VigiBase, the WHO global ICSR database system: basic facts","volume":"42","author":"Lindquist","year":"2008","journal-title":"Drug Inf J"},{"key":"10.1016\/j.seizure.2021.07.011_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2020.114976","article-title":"Towards a comprehensive safety understanding of granulocyte-colony stimulating factor biosimilars in treating chemotherapy associated febrile neutropenia: Trends from decades of data","author":"Rastogi","year":"2020","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.seizure.2021.07.011_bib0026","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00002018-200730070-00011","article-title":"Bayesian confidence propagation neural network","volume":"30","author":"Bate","year":"2007","journal-title":"Drug Saf"},{"key":"10.1016\/j.seizure.2021.07.011_bib0027","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1177\/2168479015589822","article-title":"Quantitative methods for the identification of signals for individual case safety reports in India","volume":"49","author":"Vivekanandan","year":"2015","journal-title":"Therap Innov Regul Sci"},{"key":"10.1016\/j.seizure.2021.07.011_bib0028","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.seizure.2021.07.011_bib0029","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2165\/00002018-200225060-00010","article-title":"Use of measures of disproportionality in pharmacovigilance","volume":"25","author":"Egberts","year":"2002","journal-title":"Drug Saf"},{"key":"10.1016\/j.seizure.2021.07.011_bib0030","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1109\/TITB.2005.855566A","article-title":"Evaluation of statistical association measures for the automatic signal generation in pharmacovigilance","volume":"9","author":"Roux","year":"2005","journal-title":"IEEE Trans Inf Technol Biomed"},{"key":"10.1016\/j.seizure.2021.07.011_bib0031","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2007.08.036","article-title":"Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel","volume":"58","author":"Halevy","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.seizure.2021.07.011_bib0032","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/S0140-6736(98)05418-X","article-title":"Risk of Stevens-Johnson syndrome and toxic epider mal necrolysis during first weeks of antiepileptic therapy: a case-control study","volume":"353","author":"Rzany","year":"1999","journal-title":"Lancet N Am Ed"},{"key":"10.1016\/j.seizure.2021.07.011_bib0033","unstructured":"USFDA Carbamazepine Prescribing Information to Include Recommendation of Genetic Test for Patients with Asian Ancestry-Connection of genetic information with medication use can improve safe use of product. 2007."},{"key":"10.1016\/j.seizure.2021.07.011_bib0034","doi-asserted-by":"crossref","DOI":"10.1038\/428486a","article-title":"A marker for Stevens\u2013Johnson syndrome","volume":"428","author":"Chung","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.seizure.2021.07.011_bib0035","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/tpj.2013.40","article-title":"HLA-A* 31: 01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis","volume":"14","author":"Genin","year":"2014","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.seizure.2021.07.011_bib0036","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jad.2015.03.018","article-title":"Association between HLA-DRB1* 0405,-DQB1* 0401 and-DQA1* 0303 alleles and lamotrigine-induced cutaneous adverse drug reactions. A pilot case-control study from Japan","volume":"179","author":"Ito","year":"2015","journal-title":"J Affect Disord"},{"key":"10.1016\/j.seizure.2021.07.011_bib0037","doi-asserted-by":"crossref","first-page":"44","DOI":"10.4103\/2229-5151.94904","article-title":"Stevens-Johnson syndrome induced by sodium valproate monotherapy","volume":"2","author":"Naveen","year":"2012","journal-title":"Int J Crit Illness Inj Sci"},{"key":"10.1016\/j.seizure.2021.07.011_bib0038","first-page":"42","article-title":"Antiepileptic drugs-induced Stevens\u2013Johnson syndrome: a case Series","volume":"8","author":"Trivedi","year":"2016","journal-title":"J Basic Clin Pharmacy"},{"key":"10.1016\/j.seizure.2021.07.011_bib0039","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","article-title":"Medication use and the risk of Stevens\u2013Johnson syndrome or toxic epidermal necrolysis","volume":"333","author":"Roujeau","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.seizure.2021.07.011_bib0040","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s11096-018-0693-x","article-title":"Pharmacovigilance in China: development and challenges","volume":"40","author":"Zhao","year":"2018","journal-title":"Int J Clin Pharmacy"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131121002430?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131121002430?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T02:02:17Z","timestamp":1761012137000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131121002430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":40,"alternative-id":["S1059131121002430"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2021.07.011","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Severe cutaneous adverse reactions in Asians: Trends observed in culprit anti-seizure medicines using VigiBase\u00ae","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2021.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd on behalf of British Epilepsy Association.","name":"copyright","label":"Copyright"}]}}